Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models

IntroductionCombining CpG oligodeoxynucleotides with anti-OX40 agonist antibody (CpG+OX40) is able to generate an effective in situ vaccine in some tumor models, including the A20 lymphoma model. Immunologically “cold” tumors, which are typically less responsive to immunotherapy, are characterized b...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander A. Pieper, Luke M. Zangl, Dan V. Speigelman, Arika S. Feils, Anna Hoefges, Justin C. Jagodinsky, Mildred A. Felder, Noah W. Tsarovsky, Ian S. Arthur, Ryan J. Brown, Jen Birstler, Trang Le, Peter M. Carlson, Amber M. Bates, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Amy K. Erbe, Paul M. Sondel, Ravi B. Patel, Zachary S. Morris
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
In situ vaccine
cold tumor models
OX40 agonist
CpG – oligonucleotides
radiation therapy
radioimmunotherapy
Immunologic diseases. Allergy
RC581-607
Online Access:https://doaj.org/article/3c1a8a46c1f247d4b0ac7ee7662a9e57
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items